| Bio-Pharmaceuticals and Biotechnology | Stem cell therapy, specialty drug manufacturing, new drug discovery, molecular diagnostics, clinical research services (CRO). | Collaborations with research centers, expertise in regenerative medicine, and emerging IP portfolio. | Healthcare providers, pharmaceutical companies, research institutes; B2B and B2C. | New drug discovery and specialty drug manufacturing expected to yield higher margins. | | | Planned revenue from drug sales, research collaborations, clinical trial services, and bio-pharma trading. | Project-based, service contracts, and product sales upon commercialization. | Growth driven by innovation in stem cells, new molecular entities, and expanding clinical research demand. | |
